The cannabinoid CB1 receptor antagonist AM251 does not modify methamphetamine reinstatement of responding

Sherin Y. Boctor, Joe L. Martinez, Wouter Koek, Charles P. France

Resultado de la investigación: Articlerevisión exhaustiva

19 Citas (Scopus)

Resumen

Cannabinoid CB1 receptor antagonists can decrease methamphetamine self-administration. This study examined whether the CB1 receptor antagonist AM251 [N-(piperidin-1-yl)-5-(4-indophonyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide] modifies reinstatement in rats that previously self-administered methamphetamine. Rats (n = 10) self-administered methamphetamine (0.1 mg/kg/infusion) under a fixed ratio 2 schedule. Non-contingent methamphetamine (0.01-1.78 mg/kg, i.v.) yielded responding for saline (reinstatement) that was similar to responding for self-administered methamphetamine. AM251 (0.032-0.32, i.v.) did not affect methamphetamine-induced reinstatement but significantly attenuated {up triangle, open}9-tetrahydrocannabinol (2.0 mg/kg, i.p.)-induced hypothermia. These data fail to support a role for endogenous cannabinoids or cannabinoid CB1 receptors in reinstatement and, therefore, relapse to stimulant abuse.

Idioma originalEnglish (US)
Páginas (desde-hasta)39-43
Número de páginas5
PublicaciónEuropean Journal of Pharmacology
Volumen571
N.º1
DOI
EstadoPublished - sept. 24 2007

ASJC Scopus subject areas

  • Pharmacology

Huella

Profundice en los temas de investigación de 'The cannabinoid CB1 receptor antagonist AM251 does not modify methamphetamine reinstatement of responding'. En conjunto forman una huella única.

Citar esto